Screening Colonoscopy Among Colorectal Cancer Survivors Insured by Medicaid
Real-world Impact of Availability of Adjuvant Therapy on Outcomes in Patients With Resected Pancreatic Adenocarcinoma
Adjuvant Radiation Therapy Increases Overall Survival in Node-Positive Gastric Cancer Patients With Aggressive Surgical Resection and Lymph Node Dissection
Activity of Thalidomide and Capecitabine in Patients With Advanced Hepatocellular Carcinoma
Adjuvant Chemotherapy and Risk of Gastrointestinal, Hematologic, and Cardiac Toxicities in Elderly Patients With Stage III Colon Cancer
Randomized Prospective Phase II Study to Compare the Combination Chemotherapy Regimen Epirubicin, Cisplatin, and 5-Fluorouracil With Epirubicin, Cisplatin, and Capecitabine in Patients With Advanced or Metastatic Gastric Cancer
Pathologic Response to Short Intensified Taxane-free Neoadjuvant Chemotherapy in Patients with Highly Proliferative Operable Breast Cancer
Epidermal Growth Factor Genetic Variation Associated With Advanced Cervical Cancer in Younger Women
Phase II, Multicenter, Uncontrolled Trial of Single-agent Capecitabine in Patients With Non-clear Cell Metastatic Renal Cell Carcinoma
A Phase II Trial of Erlotinib as Maintenance Treatment After Gemcitabine Plus Platinum-based Chemotherapy in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
Is There a Clinical Benefit to Adaptive Planning During Tomotherapy in Patients with Head and Neck Cancer at Risk for Xerostomia?
Comparative Effectiveness of Filgrastim, Pegfilgrastim, and Sargramostim as Prophylaxis Against Hospitalization for Neutropenic Complications in Patients With Cancer Receiving Chemotherapy
Minimal Residual Disease is a Prognostic Marker for Neuroblastoma With Bone Marrow Infiltration
Second Tumors in Pediatric Patients Treated With Radiotherapy to the Central Nervous System
Pseudoprogression in Patients With Glioblastoma Multiforme After Concurrent Radiotherapy and Temozolomide
Why is Partial-breast Irradiation Still Investigational
Integrating Radioembolization With Chemotherapy in the Treatment Paradigm for Unresectable Colorectal Liver Metastases
ACR Appropriateness Criteria® Follow-up and Retreatment of Brain Metastases
Do G-CSF Schedules Make a Difference?